Jefferies analyst Brian Tanquilut initiated coverage of Pennant Group (PNTG) with a Buy rating and $30 price target The firm is bullish on the home health, saying the sector is a share gainer given its low-cost nature and patient preference for this site of care. As investors seek ways to play this thesis, Pennant sticks out given its low-teens EBITDA growth, driven by industry tailwinds and solid execution, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG:
- Pennant Group management to meet with Oppenheimer
- Pennant Group management to meet with Truist
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- UnitedHealth (UNH) Divests Home Health and Hospice Assets Worth $146.5M to Pennant
- Pennant Group Expands with Strategic Acquisition in Southeast